Development of hepatocellular carcinoma in a patient 13 years after sustained virological response to interferon against chronic hepatitis C: A case report

Cases Journal

Volumn 2, Issue 1, 2009, Pages

  Mashitani, Tsuyoshi ^a   Yoshiji, Hitoshi ^a   Yamazaki, Masaharu ^a   Ikenaka, Yasuhide ^a   Noguchi, Ryuichi ^a   Ishikawa, Masatoshi ^a   Kawaratani, Hideto ^a   Matsuo, Norihide ^a   Uemura, Masahito ^a   Yamao, Junichi ^a   Fujimoto, Masao ^a   Mitoro, Akira ^a   Toyohara, Masahisa ^a   Yoshida, Motoyuki ^a   Sawai, Masayoshi ^a   Morioka, Chie ^a   Tsujimoto, Tatsuhiro ^a   Kitade, Mitsuteru ^a   Kaji, Kosuke ^a   Aihara, Yosuke ^a   Fukui, Hiroshi ^a   more..

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON;

AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SURGERY; CASE REPORT; CHEMOEMBOLIZATION; FOLLOW UP; HEPATITIS C; HISTOPATHOLOGY; HUMAN; JAPANESE; LIVER CELL CARCINOMA; MALE; MULTIMODALITY CANCER THERAPY; STEREOTACTIC RADIOSURGERY; TUMOR DIFFERENTIATION; VIRUS CARCINOGENESIS;

EID: 77950626370     PISSN: 17571626     EISSN: None     Source Type: Journal    
DOI: 10.1186/1757-1626-2-18     Document Type: Article

References (15)

1. Bosch FX, Ribes J, Borras J: Epidemiology of primary liver cancer. Semin Liver Dis 1999, 19:271-285.
2. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998, 339:1485-1492.
3. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982.
4. Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, Tsubota A, Nakamura I, Murashima N, Kumada H, Kawanishi M: Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999, 29:1124-1130. (Pubitemid 29168746)
5. Yoshida H, Tateishi R, Arakawa Y, Sata M, Fujiyama S, Nishiguchi S, Ishibashi H, Yamada G, Yokosuka O, Shiratori Y, Omata M: Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Gut 2004, 53:425-430. (Pubitemid 38241342)
6. Makiyama A, Itoh Y, Kasahara A, Imai Y, Kawata S, Yoshioka K, Tsubouchi H, Kiyosawa K, Kakumu S, Okita K, Hayashi N, Okanoue T: Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. Cancer 2004, 101:1616-1622. (Pubitemid 39318909)
7. Kobayashi S, Takeda T, Enomoto M, Tamori A, Kawada N, Habu D, Sakaguchi H, Kuroda T, Kioka K, Kim SR, Kanno T, Ueda T, Hirano M, Fujimoto S, Jomura H, Nishiguchi S, Seki S: Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients. Liver Int 2007, 27:186-191. (Pubitemid 46680721)
8. Toyoda H, Kumada T, Honda T, Hayashi K, Katano Y, Nakano I, Hayakawa T, Fukuda Y: Analysis of hepatocellular carcinoma tumor growth detected in sustained responders to interferon in patients with chronic hepatitis C. J Gastroenterol Hepatol 2001, 16:1131-1137. (Pubitemid 32990109)
9. Suganami F, Tomiyama Y, Ohmoto K, Kawase T, Yoshioka N, Shibata N, Yoshida K, Kuboki M, Yamamoto S: [Hepatocellular carcinoma occurring after 11 year-long sustained viral response to interferon therapy for chronic hepatitis C]. Nippon Shokakibyo Gakkai Zasshi 2007, 104:809-814.
10. Aizawa Y, Shibamoto Y, Takagi I, Zeniya M, Toda G: Analysis of factors affecting the appearance of hepatocellular carcinoma in patients with chronic hepatitis C. A long term follow-up study after histologic diagnosis. Cancer 2000, 89:53-59. (Pubitemid 30451273)
11. Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Koida I, Arase Y, Fukuda M, Chayama K, Murashima N, Kumada H: Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol 1998, 28:930-938. (Pubitemid 28275969)
12. Khan MH, Farrell GC, Byth K, Lin R, Weltman M, George J, Samarasinghe D, Kench J, Kaba S, Crewe E, Liddle C: Which patients with hepatitis C develop liver complications? Hepatology 2000, 31:513-520. (Pubitemid 30078621)
13. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB: Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 2005, 54:533-539. (Pubitemid 40403031)
14. Pollicino T, Squadrito G, Cerenzia G, Cacciola I, Raffa G, Craxi A, Farinati F, Missale G, Smedile A, Tiribelli C, Villa E, Raimondo G: Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology 2004, 126:102-110. (Pubitemid 38040728)
15. Tamori A, Nishiguchi S, Shiomi S, Hayashi T, Kobayashi S, Habu D, Takeda T, Seki S, Hirohashi K, Tanaka H, Kubo S: Hepatitis B virus DNA integration in hepatocellular carcinoma after interferon-induced disappearance of hepatitis C virus. Am J Gastroenterol 2005, 100:1748-1753. (Pubitemid 41648429)